Original ArticleIndividualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: An open, prospective randomized controlled trial
Section snippets
Material
Prothrombin complex concentrate (Cofact®, licensed in the Netherlands under RVG 17060, Sanquin, Amsterdam, The Netherlands) is manufactured from human plasma obtained from selected, voluntary, non-remunerated donors. Each donation has been tested and found negative for HIV 1–2, HBV, HCV, and HTLV I/II and treponema pallidum by serological and/or NAT testing methods. Virus reducing steps are incorporated in the production process, i.e., a solvent detergent virus inactivation step, as well as a
Results
In this open, prospective, randomized, controlled trial, all 93 patients were included in the intention-to-treat analysis. The characteristics of the patients of group A and B were found to be similar in sex, age, bodyweight, body mass index, number of bleedings and interventions, and the initial-INR and target-INR (Table 2).
For reaching the target-INR at 15 min after the first dosage of PCC, a statistically significant difference was found in the number of patients receiving the individualized
Discussion
In this study, a “standard” dosage of 20 ml PCC is compared with an individualized dosing based on the patient's initial-INR, the target-INR and bodyweight. The 20 ml dosage was the volume of PCC that is regularly being used, like in the hospital where the study was performed. Of the patients treated according to the individualized dosing regimen, significantly more patients attained the target-INR 15 min after administration of PCC, i.e., 89% versus 43% of patients treated with a standard dose.
Acknowledgments
The statistical analysis was performed by H.E. Nienhuis; J.C. Drenth contributed to earlier versions of this article.
References (31)
- et al.
The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest
(2004) - et al.
Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy
Lancet
(1996) - et al.
Managing oral anticoagulant therapy
Chest
(2001) Rational, high quality laboratory monitoring before, during, and after infusion of prothrombin complex concentrates
Thromb Res
(1999)- et al.
Management of oral anticoagulant-induced intracranial haemorrhage
Blood Rev
(1998) - et al.
Pharmacokinetics, thrombogenicity and safety of a double-treated prothrombin complex concentrate
Thromb Res
(1993) - et al.
Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR > 10
Thromb Res
(2004) - et al.
Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation
Thromb Res
(2004) - et al.
The management of coumarin-induced over-anticoagulation annotation
Br J Haematol
(2001) - et al.
Bleeding complications in oral anticoagulant therapy. An analysis of risk factors
Arch Intern Med
(1993)
Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin optimized outpatient follow-up study group
Ann Intern Med
Analysis and occurrence of adverse events with oral anticoagulant therapy
Semin Thromb Hemost
Management and prognosis of life-threatening bleeding during warfarin therapy. National Consortium of Anticoagulation Clinics
Arch Intern Med
Guidelines on oral anticoagulation: third edition
Br J Haematol
Use of factor IX complex in warfarin-related intracranial hemorrhage
Neurosurgery
Cited by (143)
Safety and efficacy of fixed versus variable-dose prothrombin complex concentrate for emergent reversal of vitamin K antagonists: A systematic review and meta-analysis
2024, American Journal of Emergency MedicineA Neutral Trial With an Improper Noninferiority Margin
2022, Annals of Emergency MedicineEvaluation of fixed versus variable dosing of 4-factor prothrombin complex concentrate for emergent warfarin reversal
2021, American Journal of Emergency MedicineProtocolized use of Factor Eight Inhibitor Bypassing Activity (FEIBA) for the reversal of warfarin induced coagulopathy
2020, American Journal of Emergency MedicineCitation Excerpt :We found that, similar to other studies [18,19], a protocolized fixed dose of FEIBA based on initial INR was effective in reversing elevated INR. This also provided simplicity and low total dosing compared with previous weight-adjusted protocols [35]. The need for additional dosing of FEIBA was only 16.3% in our study, and repeat INR measurements after 30 min were important to monitor appropriate reversal of elevated INR.
Management of Intracranial Hemorrhage in the Anticoagulated Patient
2018, Neurosurgery Clinics of North America